Given the current enthusiasm for PD-1 inhibitors such as pembrolizumab and nivolumab, we anticipate further data on the utility of PD-1/PD-L1 expression in predicting response to these immune checkpoint inhibitors and their novel combination regimens in AITL, although recent data suggests modest activity and risk of hyperprogression in patients treated with nivolumab alone (120). Here, PDCD1 is linked to angioimmunoblastic T-cell lymphoma.